A Phase 1, Open-Label, Dose-Finding Study Of ASN007 In Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2018
At a glance
- Drugs ASN 007 (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Asana BioSciences
- 29 Jan 2018 Status changed from planning to recruiting.
- 05 Jan 2018 New trial record
- 03 Jan 2018 According to an Asana Biosciences media release, the US FDA has accepted the IND application for ASN007.